PJP:NYE-Invesco Dynamic Pharmaceuticals ETF (USD)

ETF | Health |

Last Closing

USD 87.3233

Change

-1.22 (-1.38)%

Market Cap

N/A

Volume

9.02K

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-10-21 )

Largest Industry Peers for Health

Symbol Name Price(Change) Market Cap
XLV Health Care Select Sector SPDR..

-1.80 (-1.18%)

USD 41.35B
FHLC Fidelity® MSCI Health Care In..

-0.85 (-1.17%)

USD 2.95B
FXH First Trust Health Care AlphaD..

-1.37 (-1.24%)

USD 1.22B
XHE SPDR® S&P Health Care Equipme..

-1.19 (-1.34%)

USD 0.22B
IDNA iShares Genomics Immunology an..

-0.39 (-1.58%)

USD 0.14B
SBIO ALPS Medical Breakthroughs ETF

-0.71 (-1.78%)

USD 0.12B
XHS SPDR® S&P Health Care Service..

-1.52 (-1.58%)

USD 0.08B
HTEC Robo Global® Healthcare Techn..

-0.34 (-1.17%)

USD 0.06B
BBP Virtus LifeSci Biotech Product..

-0.76 (-1.20%)

USD 0.02B
BBC Virtus LifeSci Biotech Clinica..

-0.67 (-2.19%)

USD 0.01B

ETFs Containing PJP

N/A

Market Performance

  Market Performance vs. Industry/Classification (Health) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 14.75% 90% A- 68% D+
Dividend Return N/A N/A N/A N/A N/A
Total Return 14.75% 90% A- 69% C-
Trailing 12 Months  
Capital Gain 25.30% 81% B- 60% D-
Dividend Return N/A N/A N/A N/A N/A
Total Return 25.30% 81% B- 63% D
Trailing 5 Years  
Capital Gain 49.17% 81% B- 72% C
Dividend Return N/A N/A N/A N/A N/A
Total Return 49.17% 81% B- 72% C
Average Annual (5 Year Horizon)  
Capital Gain 6.65% 62% D 59% D-
Dividend Return 7.23% 62% D 54% F
Total Return 0.59% 58% F 14% F
Risk Return Profile  
Volatility (Standard Deviation) 12.98% 76% C+ 71% C-
Risk Adjusted Return 55.74% 76% C+ 72% C
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

What to not like:

There is nothing we particularly dislike